Dulaglutide Outperforms Liraglutide for Blood Sugar Control in Real-World Diabetes Care

In a real-world study of 2,418 type 2 diabetes patients, dulaglutide reduced HbA1c more than liraglutide (-0.24% difference), with similar effectiveness to exenatide once weekly.

Morieri, Mario Luca et al.·Metabolism: clinical and experimental·2020·Moderate EvidenceObservational
RPEP-05011ObservationalModerate Evidence2020RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Observational
Evidence
Moderate Evidence
Sample
N=2418
Participants
2,418 type 2 diabetes patients at specialist clinics (849 dulaglutide, 1,371 liraglutide, 198 exenatide OW) from 2010-2018

What This Study Found

Dulaglutide reduced HbA1c 0.24% more than liraglutide in real-world clinical practice (p=0.003), confirmed by meta-analysis of observational studies.

Key Numbers

Dulaglutide vs liraglutide: -0.24% HbA1c (p=0.003); meta-analysis vs exeOW: -0.19% HbA1c (p=0.003), -0.8 kg (p=0.007); 5.9 month follow-up

How They Did This

Retrospective multicenter real-world study (2010-2018) with propensity score matching, plus meta-analysis of similar observational studies covering the same drug comparisons.

Why This Research Matters

Real-world data often differs from clinical trials. This study helps clinicians choose between GLP-1 drugs based on actual patient outcomes in routine care, not just idealized trial settings.

The Bigger Picture

As GLP-1 receptor agonists become first-line diabetes treatments, head-to-head real-world comparisons help guide clinical decision-making beyond what controlled trials alone can show.

What This Study Doesn't Tell Us

Observational design with potential residual confounding; liraglutide under-dosing likely influenced results; exenatide group was small (n=198); short follow-up of ~6 months.

Questions This Raises

  • ?Would dulaglutide still outperform liraglutide if all patients received optimal dose titration?
  • ?How do these real-world comparisons change with semaglutide added to the analysis?
  • ?Do the HbA1c differences translate to meaningful differences in cardiovascular or mortality outcomes?

Trust & Context

Key Stat:
-0.24% HbA1c advantage Dulaglutide reduced HbA1c significantly more than liraglutide in real-world clinical practice
Evidence Grade:
Large real-world study with propensity score matching and supporting meta-analysis, but observational design cannot fully eliminate confounding.
Study Age:
Published in 2020; the GLP-1 RA landscape has since expanded with semaglutide becoming a dominant option not included in this comparison.
Original Title:
Effectiveness of dulaglutide vs liraglutide and exenatide once-weekly. A real-world study and meta-analysis of observational studies.
Published In:
Metabolism: clinical and experimental, 106, 154190 (2020)
Database ID:
RPEP-05011

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study

Watches what happens naturally without intervening.

What do these levels mean? →

Frequently Asked Questions

Is dulaglutide better than liraglutide for diabetes?

In real-world practice, dulaglutide reduced HbA1c 0.24% more than liraglutide, though this may partly reflect liraglutide under-dosing rather than inherent drug superiority.

What is HbA1c and why does it matter?

HbA1c measures average blood sugar over 2-3 months. Lower HbA1c means better diabetes control and reduced risk of complications like heart disease, kidney damage, and nerve problems.

Read More on RethinkPeptides

Cite This Study

RPEP-05011·https://rethinkpeptides.com/research/RPEP-05011

APA

Morieri, Mario Luca; Rigato, Mauro; Frison, Vera; Simioni, Natalino; D'Ambrosio, Michele; Tadiotto, Federica; Paccagnella, Agostino; Lapolla, Annunziata; Avogaro, Angelo; Fadini, Gian Paolo. (2020). Effectiveness of dulaglutide vs liraglutide and exenatide once-weekly. A real-world study and meta-analysis of observational studies.. Metabolism: clinical and experimental, 106, 154190. https://doi.org/10.1016/j.metabol.2020.154190

MLA

Morieri, Mario Luca, et al. "Effectiveness of dulaglutide vs liraglutide and exenatide once-weekly. A real-world study and meta-analysis of observational studies.." Metabolism: clinical and experimental, 2020. https://doi.org/10.1016/j.metabol.2020.154190

RethinkPeptides

RethinkPeptides Research Database. "Effectiveness of dulaglutide vs liraglutide and exenatide on..." RPEP-05011. Retrieved from https://rethinkpeptides.com/research/morieri-2020-effectiveness-of-dulaglutide-vs

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.